Biocompatible 3-D tracking system advances robotic surgery

Surgeons may have a new competitor in the recently developed biocompatible near-infrared 3D tracking system used in the first smart tissue autonomous robot (STAR) surgery. The system improves upon current manual and robot-assisted surgeries with advanced 3D visibility and accuracy.

A study developed at the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children's National Health System and funded by the National Institutes of Health outlines the benefits of this surgical system in live subjects, showcasing its 3D tissue tracking abilities and millimeter accuracy.

"A fundamental challenge in soft-tissue surgery is that target tissue moves and deforms, becomes occluded by blood or other tissue, which makes it difficult to differentiate from surrounding tissue," said Axel Krieger, Ph.D., senior author on the study and program lead for Smart Tools at the Sheikh Zayed Institute. "By enabling accurate tracking of tools and tissue in the surgical environment, this innovative work has the potential to improve many applications for manual and robot-assisted surgery."

The 3D system is made up of biocompatible near-infrared fluorescent (NIRF) markers with a fused plenoptic near-infrared camera tracking system, giving the system the ability to overcome blood and tissue occlusion. The system showed tracking accuracies at 1.61mm, that only decreased to 1.71mm when covered in blood and tissue, making for higher quality and consist suturing for reduced leakage.

"This work describes the 'super human eyes' and a bit of 'intelligence' of our STAR robotic system, making tasks such as soft tissue surgery on live subjects possible," explains Peter C. Kim, M.D., vice president and associate surgeon in chief of the Sheikh Zayed Institute.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.